DE-THE-LYCRA-COMPANY
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that it is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. The LYCRA Company Pavilion in Hall 4.1 (Booth E56) features 931 square meters of exhibit space and 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827097449/en/
The LYCRA Company is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. Its pavilion in Hall 4.1 (Booth E56) features 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.” Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how bio-derived LYCRA® fiber made with QIRA® can help accelerate decarbonization in the fashion industry. (Photo: Business Wire)
The LYCRA Company will highlight products designed to meet consumer needs and help reduce the environmental impact of apparel products:
- Bio-derived LYCRA® fiber made with QIRA®, the industry’s first renewable spandex available at scale, will launch in the first half of 2025. Made from annually grown field corn, it's expected to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* while delivering equivalent performance to the original fiber. Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how this patented innovation can help accelerate decarbonization in the fashion industry.
- LYCRA® FiT400™ fiber is a unique bicomponent fiber engineered to optimize the comfort and performance of knits while delivering a durable, soft hand feel, all-day stretch, long-lasting fit, and cooling comfort. This Global Recycled Standard-certified fiber contains 60% recycled PET and 14.4% bio-derived resources.
- COOLMAX® EcoMade fiber made from 100% textile waste delivers cool and dry comfort to various garment types, while THERMOLITE® EcoMade fiber made from 100% textile waste adds lightweight warmth.
“We are thrilled to showcase our sustainable solutions at Intertextile that will help our customers reduce their carbon footprint and support their sustainability goals,” said Jason Wang, vice president, Asia. “We look forward to helping attendees find the consumer-driven, market-relevant branded solutions they need to take their business to the next level.”
The LYCRA Company will also showcase LYCRA® ADAPTIV fiber, one of the company’s fastest-growing products. Brands and retailers worldwide appreciate how it enables inclusive sizing and delivers a second-skin fit, enhanced comfort in motion, and greater functionality to activewear, intimate apparel, denim, and more. Regina Miracle, a leading garment maker and a key value chain partner of The LYCRA Company, will exhibit garment samples.
The booth will also feature garment samples of new LYCRA FitSense® denim technology, a targeted shaping innovation for stretch denim to deliver a customizable fit to different body types and shapes, a breakthrough for the industry launched this year. Through a combination of fiber, fabric, and garment processing technologies, this discreet and invisible solution retains the authentic denim look and feel that consumers desire.
To learn more about The LYCRA Company’s latest innovations and commitment to a more sustainable future, visit Intertextile Booth E56 in Hall 4.1 and Booth A36 in Hall 5.1, or visit this website.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA® FiT400™, LYCRA FitSense®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827097449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom